The search for an effective treatment for Alzheimer’s disease has been riddled with failures, but a promising new drug could serve as a rare success story for those living with mild forms of the condition.
Biogen Idec, a Massachusetts-based company, announced that a drug they’re testing effectively slowed the mental decline of some patients and reduced levels of amyloid plaques in their brains. Although the results are from an early-stage study, they offer hope of finding the so far elusive drug to battle the underlying causes of the disease.
The drug, called aducanumab, is an antibody that attacks amyloid plaques, which are widely believed to be the underlying cause of Alzheimer’s disease. The study included 166 patients with minimal to mild Alzheimer’s symptoms. Patients were split into four groups: low, medium and high doses of the drug, or else a placebo, for 54 weeks. Researchers evaluated the effectiveness of the drug by monitoring amyloid plaque levels in participants’ brains and by using two clinical tests to measure cognitive function.
Low doses of the drug didn’t significantly change brain plaque. But both medium and high doses measurably reduced plaque levels, researchers say. What’s more, high doses of the drug were found to slow patients’ mental declines over the 54-week period. Compared to placebo, patients exhibited 70 percent less of a mental decline.
The results are promising, but there’s still a long road to travel before aducanumab is an accepted treatment of Alzheimer’s disease. At high doses some patients suffered side effects, including brain swelling. Headaches were common too.
And there are more rigorous trials yet to come. The company is planning the design of a large, late-stage study of the drug that will include more than 1,000 patients. Biogen hopes to enroll patients later this year, pending approval from the Food and Drug Administration.
Read full, original article: Promising Alzheimer’s Drug Slows Cognitive Decline
